Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 May;56(5):965-72.
doi: 10.1007/s00125-013-2841-0. Epub 2013 Feb 3.

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Affiliations
Meta-Analysis

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

S Calanna et al. Diabetologia. 2013 May.

Abstract

Aims/hypothesis: We carried out a systematic review of clinical studies investigating glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes and non-diabetic controls and performed meta-analyses of plasma total GLP-1 concentrations during an OGTT and/or meal test.

Methods: Random effects models for the primary meta-analysis and random effects meta-regression, subgroup and regression analyses were applied.

Results: Random effects meta-analysis of GLP-1 responses in 22 trials during 29 different stimulation tests showed that patients with type 2 diabetes (n = 275) and controls without type 2 diabetes (n = 279) exhibited similar responses of total GLP-1 (p = NS) as evaluated from peak plasma concentrations (weighted mean difference [95% CI] 1.09 pmol/l [-2.50, 4.67]), total AUC (tAUC) (159 pmol/l × min [-270, 589]), time-corrected tAUC (tAUC min⁻¹) (0.99 pmol/l [-1.28, 3.27]), incremental AUC (iAUC) (-122 pmol/l × min [-410, 165]) and time-corrected iAUC (iAUC min⁻¹) (-0.49 pmol/l [-2.16, 1.17]). Fixed effects meta-analysis revealed higher peak plasma GLP-1 concentrations in patients with type 2 diabetes. Subgroup analysis showed increased responses after a liquid mixed meal test (peak, tAUC and tAUC min⁻¹) and after a 50 g OGTT (AUC and tAUC min⁻¹), and reduced responses after a solid mixed meal test (tAUC min⁻¹) among patients with type 2 diabetes. Meta-regression analyses showed that HbA1c and fasting plasma glucose predicted the outcomes iAUC and iAUC min⁻¹, respectively.

Conclusions/interpretation: The present analysis suggests that patients with type 2 diabetes, in general, do not exhibit reduced GLP-1 secretion in response to an OGTT or meal test, and that deteriorating glycaemic control may be associated with reduced GLP-1 secretion.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Meta-analysis of plasma total GLP-1 responses during an OGTT or meal test evaluated from tAUC (pmol/l×min) using a random effects model. WMD, weighted mean difference. Capital letters indicate different GLP-1 secretory stimuli in the same study
Fig. 2
Fig. 2
Meta-analysis of peak plasma total GLP-1 concentrations (pmol/l) during an OGTT or meal test using a fixed effects model. WMD, weighted mean difference. Capital letters indicate different GLP-1 secretory stimuli in the same study
Fig. 3
Fig. 3
Subgroup analysis, according to mean HbA1c levels, of plasma total GLP-1 responses during an OGTT or meal test evaluated from iAUC (pmol/l ×min) using a random effects model. Subgroup 1 is composed of trials with mean HbA1c≤7.5% (≤58.5 mmol/mol) and subgroup 2 is composed by trials with mean HbA1c> 7.5% (>58.5 mmol/mol). WMD, weighted mean difference. Capital letters indicate different GLP-1 secretory stimuli in the same study

References

    1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–1439. - PubMed
    1. Ørskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondia-betic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest. 1991;87:415–423. - PMC - PubMed
    1. Ross SA, Dupre J. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes. 1978;27:327–333. - PubMed
    1. Tolhurst G, Reimann F, Gribble FM. Intestinal sensing of nutrients. Handb Exp Pharmacol. 2012;209:309–335. - PubMed
    1. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010;59:1765–1770. - PMC - PubMed

MeSH terms

Substances